

UNITED STATES OF AMERICA
DEPARTMENT OF HEALTH AND HUMAN SERVICES

+ + + + +

PRE-PROPOSAL CONFERENCE

RFP-HHS-BARDA-08-09:

BUILDING PANDEMIC CELL-BASED INFLUENZA
VACCINE MANUFACTURING FACILITIES

+ + + + +

FRIDAY,
SEPTEMBER 12, 2008

+ + + + +

The pre-proposal conference
convened at 9:00 a.m. in Room 325A of the
Hubert Humphrey Building, 200 Independence
Ave, SW, Washington, DC.

PRESENT FROM HHS:

MICHAEL ANGELASTRO
CHARLES CURRAN
SCHUYLER ELDRIDGE
CHRISTINA HARTMAN
ROBERT HUEBNER
VIJAYA MURTHY
PAQUETTA MYRICK-HANCOCK

MICHAEL PERDUE

THOMAS WARF

A G E N D A

INTRODUCTION3

Dr. Mike Perdue

RESPONSES TO QUESTIONS7

Mike Angelastro

BREAK 22

ADDITIONAL QUESTIONS FROM ATTENDEES 23

CLOSING REMARKS 30

Dr. Mike Perdue

1 P-R-O-C-E-E-D-I-N-G-S

2 (9:06 a.m.)

3 MR. WARF: Okay. I would like to
4 welcome everybody, and start off the
5 conference now, and introduce Dr. Michael
6 Perdue. He is the Acting Director of the
7 Pandemic Influenza program, which is now
8 changed to IEDD, which is not an explosive
9 device, talks about influenza and emerging
10 diseases. Dr. Perdue.

11 DR. PERDUE: Thanks. Yes, on
12 behalf of our division in BARDA, let me
13 welcome you to today's proceedings. And as
14 you all know, the Secretary has great interest
15 in development of cell culture produced
16 vaccines on our soil for rapid response to
17 potential pandemic, and also other emerging
18 diseases. And our group is a program
19 responsible sort of for delivering advanced
20 development and acquisition of the
21 countermeasures for pandemic flu, so I think
22 you're all aware of our role within BARDA, and

1 BARDA's role within the U.S. government.

2 Today, we have the opportunity to
3 answer questions for you, and we have our top
4 people, I assure you, from our division, as
5 well as the Contracting Office on this because
6 it is a fairly high profile endeavor and
7 contract, so we look forward to interacting
8 with you. If there's anything the program can
9 do, our division can do for you, please let me
10 know. Otherwise, I'll turn it over to these
11 guys to answer the questions. Turn it over to
12 Mike.

13 MR. ANGELASTRO: Okay. Thank you,
14 Dr. Perdue. First off, I'd like to just go
15 around on the government side of the house
16 here and do a quick introduction, make sure
17 everybody knows who the players are. My name
18 is Mike Angelastro. I'm the Contracting
19 Officer's Technical Representative, formerly
20 known as Project Officer for this
21 solicitation.

22 MR. WARF: I'm Tom Warf, and I

1 serve as the Program Manager for the overall
2 facilities program.

3 MR. CURRAN: My name is Charlie
4 Curran, and I'm here with the Office of
5 General Counsel, the General Law Division,
6 sort of give some guidance on the legal side.

7 MS. MYRICK-HANCOCK: Good morning.
8 My name is Paquetta Hancock. I'll be the
9 Contracting Officer for this requirement.

10 DR. HUEBNER: I'm Bob Huebner.
11 I'm a Senior Program Manager working in cell
12 based vaccines and stockpile.

13 MR. ELDRIDGE: Schuyler Eldridge,
14 Contracting Officer.

15 MS. MURTHY: Vijaya Murthy,
16 Contract Specialist.

17 MS. HARTMAN: Christina Hartman,
18 HHS.

19 MR. ANGELASTRO: Good. Thank you.
20 I'm now going to turn it over to Paquetta, who
21 will give you some brief overview of today's
22 proceedings, how we're going to structure the

1 meeting.

2 MS. MYRICK-HANCOCK: Okay. I'd
3 just like to mention two things. First of
4 all, I'd like to make sure that everyone
5 signed in that's actually here in attendance.
6 If there is anyone who hasn't signed in,
7 please do so.

8 What we're going to do is we
9 prepared some responses to the questions that
10 were submitted by the deadline that we'd like
11 to go through. Mike is going to take you
12 through a slide presentation with those
13 responses.

14 We're also going to give -- then
15 we're going to have a break, 15-20 minutes.
16 We're going to allow you during the
17 presentation to note your additional follow-up
18 questions that you may have on these index
19 cards. During the break, we'll collect these,
20 review it, and see if we can provide you with
21 the additional responses for them. And if
22 anyone needs more, please let me know.

1 MR. ANGELASTRO: Also, as you may
2 or may not have noticed, the room is wired.
3 We're recording the proceedings today, so that
4 a transcript can be created for posting on
5 FedBizOpps. All right.

6 MS. MYRICK-HANCOCK: There's also
7 a copy of the handout.

8 MR. ANGELASTRO: What Paquetta is
9 distributing right now is a handout of the
10 formal responses to the questions that were
11 pre-submitted for this RFP. I have them on
12 the slide deck here. We'll go through them in
13 detail, but if you wanted to see the full
14 question, because some of the questions
15 actually had some -- a preamble to them, and
16 I wanted to make sure you have the full text.
17 So, let's get started.

18 Question number one is, "Are costs
19 associated with deliverables that are not part
20 of earlier awarded contracts to be included in
21 the overall proposal costs?" And our response
22 to that is, "Costs that support the technical

1 elements of this RFP, but are currently funded
2 with other U.S. government contracts should be
3 identified as such in the business proposal.
4 Those costs should not be included in the
5 final estimate." Of course, that all goes
6 into the business proposal element of the
7 contract, so we want to avoid double billing
8 situations, as well as confusion with other
9 existing government contracts.

10 Question number two, "What should
11 be the basis for projected pandemic vaccine
12 strain yields", a manufacturing or production
13 side of the house question. So, "The U.S.
14 government will accept an average yield based
15 on the performance of influenza strains
16 manufactured as part of contracts administered
17 under other BARDA contracts." And, "Yes, the
18 offerors may assume that facility design and
19 capacity calculations can be based on yield
20 data of seasonal influenza strains on the
21 offeror's cell substrate."

22 Question number three, "Can Health

1 and Human Services clarify its position on
2 indemnification if the pandemic vaccine
3 requested to be made by Health and Human
4 Services under this RFP is not an already
5 licensed vaccine?" This is a legal question,
6 and, "The government has taken the comments
7 under consideration, weighing a number of
8 options about how to best address contractor
9 concerns in this area, and a more definitive
10 response to the question will be provided as
11 part of any amended RFP." So we're working
12 through that with our General Counsel.

13 Question number four, along
14 similar lines, legal question, "Can Health and
15 Human Services clarify the status of the U.S.
16 government's position on the issue", and the
17 issue being intellectual property, "and
18 whether or not a formal waiver for this
19 potentially restricted criteria would be
20 afforded by Health and Human Services." So
21 the issue at hand is intellectual property
22 revolving around re-assorted reverse genetics

1 technology. And, "Does HHS have an agreement
2 in place that allows other parties to use the
3 technology in conjunction with Health and
4 Human Service's affiliated warm based
5 manufacturing contracts, or in the event of a
6 pandemic?" And similar response to question
7 number three, taking that comment under
8 consideration, and we're looking at a formal
9 response for that.

10 Question number five, "Does HHS
11 anticipate amending the referenced September
12 29th proposal submission date of the RFP to a
13 later date to allow offerors to compile a
14 proposal that better meets the requirements of
15 DHHS?" And the answer to that is no, proposal
16 submission is due 3 p.m. on September 29th, so
17 we're not extending the proposal due date.
18 And the next slide outlines our aggressive
19 schedule, as Dr. Perdue has highlighted. We
20 have a time line to award that's rather
21 aggressive, but it's also a high priority of
22 the Secretary of Health and Human Services, so

1 we're shooting for a target of December 15th
2 for contract award. And as we backdated our
3 work, we realized that the last possible date
4 that we can accept the initial round of
5 proposals would be September 29th. So this is
6 an outline of what the process is, starting
7 with September 29th. October 28th is when
8 we'll determine our competitive range.
9 November 28th, the final proposals will be
10 due, after a period of Q&A between the
11 Contracting Officer and the offerors.
12 December 5th will be award recommendations to
13 our HHS Leadership, and hopefully by December
14 15th, we'll have contract award, and there'll
15 be a merry Christmas for everyone. Everybody
16 got notes on that.

17 Okay. Question number six, "To
18 what extent does Health and Human Services
19 anticipate having materials stockpiled to
20 enable fill and finish of vaccine, if such a
21 shortage of non-offeror materials should
22 occur?" So we're talking about vials, and

1 syringes and things of that sort. And the
2 materials for finishing doses will be the
3 subject of another RFP issued by BARDA. So as
4 you can tell in this RFP, if we do have a
5 declared pandemic or when we have a declared
6 pandemic, the manufacturer of the 150 million
7 doses will be a separate solicitation. And
8 then these elements will be captured in that
9 solicitation.

10 Question seven, "Assuming that an
11 offeror does not currently have funding from
12 Health and Human Services for all required
13 clinical trials for licensure of a pandemic
14 vaccine, will the clinical bridging studies to
15 be funded by Health and Human Services through
16 this mechanism include conducting clinical
17 trials required by FDA for licensure of a
18 pandemic vaccine?" And the answer to that is,
19 "The clinical bridging studies will be funded;
20 however, studies that are required by CBER to
21 achieve licensure will not be funded."

22 Question eight - the next few are

1 a little long. Question eight, "Is HHS
2 willing to modify or remove the mandatory
3 requirement for successful completion of Phase
4 I clinical trials for a mammalian cell-based
5 influenza vaccine candidate as a prerequisite
6 to the proposal submission?"

7 To answer that question,
8 specifically, "No, the mandatory requirement
9 for successful completion of Phase I clinical
10 trials for a mammalian cell-based influenza
11 vaccine candidate as a prerequisite to
12 proposal submission will not be removed."

13 The second question was, "For
14 example, can egg based seasonal or pandemic
15 influenza vaccine clinical data be submitted?"
16 The answer, "No, egg based seasonal or
17 pandemic influenza vaccine clinical data may
18 not be submitted to satisfy the mandatory
19 criteria."

20 The third question, "Can seasonal
21 mammalian cell-based influenza vaccine
22 clinical data be submitted?" And that just

1 goes back to the other question. "However,
2 clinical trial data for inter-pandemic or
3 seasonal mammalian cell-based influenza
4 vaccine candidates will satisfy this element
5 of the mandatory criteria."

6 So as we were reading the
7 questions, we interpreted the question with
8 the preamble to this that there was a concern
9 that we were only looking for pandemic
10 strains, and it's really whether we have
11 seasonal or inter-pandemic candidate on your
12 cell substrate. That clinical data will be
13 acceptable, and will satisfy the mandatory
14 criteria.

15 Question nine, "Will contractors
16 be reimbursed for their actual costs plus a
17 fixed fee subject to the limitation of costs,
18 or will their cost recovery be limited to
19 their estimated cost plus fixed fee, unless
20 actual costs are less than estimated costs?
21 Then it would be actual costs plus fixed fee,
22 as suggested in the language of the RFP,

1 regardless of whether actual costs exceed
2 estimates."

3 And the answer from our
4 Contracting Office is, "The total Cost Plus
5 Fixed Fee that has been obligated at contract
6 award cannot be exceeded without approval in
7 writing from the Contracting Officer. Actual
8 costs, however, that are billed against the
9 current obligated amount will be reimbursed up
10 to the obligated amount, as long as they are
11 reasonable, allocable, and allowable in
12 accordance with the FAR. Once the contractor
13 reaches 75 percent of the obligated amount,
14 the Contracting Officer must be notified in
15 writing in accordance with the Limitation of
16 Cost clause. At that time, BARDA will
17 determine whether or not additional funds will
18 be obligated to fund the anticipated cost
19 overrun under the contract. A determination
20 to fund the cost overrun as identified in the
21 revised estimate submitted by the Contractor
22 does not affect the fixed fee, which remains

1 unchanged in a cost overrun situation.
2 Contractors who exceed the total Cost Plus
3 Fixed Fee on the contract without notification
4 in writing from the Contracting Officer do so
5 at their own risk."

6 That's a pretty standard setup for
7 our Cost Plus Fixed Fee contracts.

8 Question ten, "Would the
9 government consider amending the RFP in some
10 way to lessen the burden on potential
11 contractors? Alternatively, will HHS consider
12 allowing the contractors to negotiate in good
13 faith new terms, or to terminate the option
14 period if circumstances in the influenza
15 market deteriorate due to technology changes,
16 or if other non-viable market conditions
17 prevail?"

18 You notice in the Q&A handout,
19 there was a lengthy preamble to this one, with
20 concerns around the market itself, and the
21 length or duration of this contract. So, "As
22 stated in the RFP, it is the commitment of the

1 offeror to maintain a facility in a manner
2 that will allow for the production of pandemic
3 influenza vaccine throughout the duration of
4 this contract. The contractor has the
5 opportunity to propose contract modifications
6 that support influenza vaccine technology
7 advancements. Please note that this contract
8 does not support the advanced development of
9 an influenza vaccine."

10 See if there's follow-up on that
11 one.

12 Question eleven, "The facility
13 fully licensed for the manufacture of an
14 influenza vaccine candidate must remain in a
15 state of readiness commensurate with the terms
16 of the contract." And, "The purpose of this
17 RFP is to support eligible contractors in the
18 design, construction and licensure of a
19 domestic facility to manufacture seasonal
20 influenza vaccines. In order to remain in a
21 state of readiness commensurate with the terms
22 of the contract, the contractor must not

1 compromise their ability to manufacture
2 licensed seasonal influenza vaccine in the
3 facility. However, if the facility is
4 utilized to manufacture other biologics, and
5 the contractor is able to maintain their
6 license to manufacture seasonal influenza,
7 then the U.S. government would not object."

8 So this was around the terms of a
9 multi-product facility, and we are not
10 supporting a multi-product facility in the
11 solicitation. However, if you can maintain
12 the licensure of your seasonal influenza
13 candidate in the facility, and still
14 manufacture other products, so be it.

15 Question 12, "May contractors
16 utilize equipment purchased under this RFP in
17 conjunction with non-contract related
18 activities at the facility so long as such
19 activities do not interfere with contract
20 performance?"

21 "Title and use rights in and to
22 any equipment purchased under this RFP will be

1 subject to provisions of Part II, Section I.5
2 of the RFP, and the provisions of the FAR Part
3 45, including, but not limited to FAR
4 45.301(f)." So you have to go back to your
5 RFP.

6 MR. CURRAN: The FAR does provide
7 guidance on the use of government-furnished
8 property, so the FAR will control what uses
9 will be permitted. Of course, the language of
10 the RFP and the FAR will determine on a
11 threshold-basis whether or not equipment is
12 government-furnished property for purposes of
13 this contract.

14 MR. ANGELASTRO: The intention of
15 the solicitation as it is now, remember from
16 our draft proposal submission, and the
17 questions that were received there, and the
18 answers that were provided by BARDA on that
19 draft is not the government's expectation to
20 have any ownership of equipment or
21 infrastructure under this solicitation per se,
22 so it's more during the course of the base

1 period of the contract, what are the ownership
2 rights? And that's going to be spelled out in
3 the language of the RFP and the FAR.

4 MR. WARF: Please note this does
5 not affect, or is not a comment upon previous
6 contracts that are already in place.

7 MR. ANGELASTRO: Correct. That
8 was also clarified in previous questions, as
9 well. If there were other contracts that
10 you're under obligation on other contracts,
11 and the government does share ownership of the
12 equipment under those other contracts, that
13 remains in effect.

14 Question thirteen, "Past
15 Performance Questionnaire is included as
16 Attachment 13. Please provide further
17 instruction as to the number of questionnaires
18 to submit."

19 "The solicitation instructs the
20 offeror to submit information concerning their
21 last three contracts completed during the last
22 three years, or information for the last three

1 contracts currently in process. It does not
2 require that the offeror submit the
3 questionnaire as part of their proposal, or
4 forward the questionnaire to their past
5 performance references. Please insure that
6 you furnish accurate, complete contact
7 information for references as specified in
8 your proposal to expedite the past performance
9 evaluation."

10 That is a key element of the
11 contract, and please follow those
12 instructions.

13 Question fourteen, "Please clarify
14 the definition of the term "Vaccine Candidate"
15 used throughout the RFP. Is the term in
16 reference to a pre-pandemic vaccine, seasonal
17 vaccine, or both?"

18 "Yes, the term "Vaccine Candidate"
19 refers to an offeror's seasonal and/or pre-
20 pandemic influenza vaccine."

21 So that we'll take a 10-15 minute
22 break, let you discussion some of the answers,

1 since you have the actual responses in front
2 of you, and then we'll reconvene for Q&A.

3 MS. MYRICK-HANCOCK: And as you
4 exit, if you could just turn your cards face
5 down here at the end of the table, and we'll
6 take a look at them and review your questions
7 during the break.

8 QUESTIONER 2: Can we discuss -

9 MS. MYRICK-HANCOCK: We'll
10 actually provide responses once we get back
11 from the break.

12 MR. CURRAN: But if you need to
13 discuss before the break, you have a question,
14 that's fine.

15 QUESTIONER 2: Yes.

16 MS. MYRICK-HANCOCK: And please
17 don't indicate -- put your names on the cards.
18 We like for this to remain anonymous.

19 (Whereupon, the proceedings went
20 off the record at 9:27:02 a.m., and went back
21 on the record at 9:47:19 a.m.)

22 MR. ANGELASTRO: All right. We're

1 going to get started. We have a few questions
2 here.

3 First off, before I get started, I
4 want to thank everyone for attending today.
5 I know Dr. Perdue mentioned earlier, but
6 appreciate you coming down and going through
7 this proposal in detail, and actually asking
8 some really good questions. A couple of them
9 have been challenging for us to actually
10 respond to, and we hope that we're able to
11 clarify some of your questions or concerns
12 regarding this requirement.

13 So the first question that we're
14 going to go through is, "Is it possible or
15 likely that an amended RFP will be issued
16 prior to the proposal submission deadline of
17 September 29th?" Myself and Paquetta both
18 feel that we will not be amending the RFP as
19 it is in the system at this time, so no, we're
20 going to keep it as it is.

21 I know there was a mention in the
22 Q&A that there may be an amended RFP to

1 incorporate responses on indemnification and
2 IT. That will be more or less discussed
3 during actual contract negotiations at the
4 signing of the contract, so incorporate
5 whatever language is necessary around that.

6 Paquetta, do you want to add
7 anything to that?

8 MS. MYRICK-HANCOCK: No, that's
9 fine.

10 MR. ANGELASTRO: Okay. That was
11 the first question. The second question
12 Charlie will take.

13 MR. CURRAN: "Can DHHS briefly
14 comment a little further on FAR 45.301? Does
15 this allow use of equipment for other
16 proprietary purposes when not used
17 specifically for production of U.S. government
18 product?"

19 The provision - excuse me - let me
20 first comment on the provision of 45.301(f).
21 45.301(f) provides that in exchange for
22 consideration as determined by the cognizant

1 Contracting Officer, and that would be at the
2 time, the contractor may use government
3 property for commercial use.

4 It goes on to say that up to 25
5 percent use for -- total use don't need to get
6 permission beyond the Contracting Officer. If
7 your use is going to exceed 25 percent, you
8 need permission from the head of the
9 contracting activity.

10 Now, the threshold question, of
11 course, is going to be whether or not the
12 equipment will be classifiable as government-
13 furnished property. Remember, this is a cost-
14 sharing contract, so some of the costs of
15 purchasing this equipment will be -- use
16 government funds, others will not. So to the
17 extent that you may foresee use of some
18 equipment for other purposes, and government
19 funds are not used, then I would advise
20 examining what the rules are, and they're set
21 out in the RFP, I think, and they're also in
22 the FAR. I don't -- from our perspective, I

1 don't think if it's not classified as
2 government-furnished property, then I don't
3 think that necessarily there will be an issue
4 from your end.

5 So there is a threshold issue of
6 whether it's government-furnished property.
7 Then there's an issue of what will happen at
8 the time, how much use. Do you intend to use
9 it for commercial purposes? When the issue
10 arises, that will be dealt with then as a
11 contract administration issue.

12 MS. MYRICK-HANCOCK: All right.
13 The third question is, "It's highly likely
14 that manufacturing costs will change
15 substantially in the 20 plus years, as
16 compared to the estimated costs that will be
17 submitted in response to the RFP. The RFP
18 indicates that the CPFF is limited to the
19 costs submitted in our application. Will
20 these costs be negotiable in the future? If
21 not, costs included in proposal will likely
22 need to incorporate contingencies for future

1 unknowns."

2 I think the pre-submitted question
3 that we responded to indicated that there is
4 a notification that has to be made to the
5 Contracting Officer once you reach 75 percent
6 of funding. That notification includes a
7 revised estimate that's submitted by the
8 contractor.

9 It's not solely a determination on
10 the part of the government whether or not
11 we're going to fund. What we're looking for,
12 once that revised estimate is submitted, is
13 for you to support the increase in costs.
14 That is subject to negotiation.

15 Once those negotiations are
16 completed, then we make a determination to
17 fund. So that's the part that was actually
18 missing from the response to the question, so
19 you do get the opportunity to negotiate those
20 costs when you provide that revised budget.
21 And that will result, once we can agree on
22 what that amount is going to be, that will

1 actually result in a modification to the
2 contract. So there is a potential there to
3 get an increase in the total estimated costs
4 on the CPFF portion of the contract.

5 We recognize that we are asking
6 you to estimate costs far in the future, and
7 we don't -- because this contract is a Cost
8 Plus Fixed Fee, that's one of the reasons it
9 is, is because we know that you can't predict
10 those costs accurately in advance. So that
11 provides you with the opportunity to come back
12 and say hey, look, there have been changes in
13 technical direction on the contract, or the
14 current market has changed such that we're
15 going to experience an increase in costs. It
16 gives you the opportunity to come in and
17 request that modification, and to support your
18 position.

19 The second part of this question
20 says, "If not, costs included in the proposal
21 will likely need to incorporate contingencies
22 for future unknowns." Unfortunately, FAR does

1 not allow us to incorporate contingencies into
2 this contract. It's not an allowable cost, so
3 the process that I've just described is the
4 only way that we can provide some flexibility
5 in the CPFF on this contract.

6 MR. ANGELASTRO: Okay. Thank you,
7 Paquetta.

8 As far as -- if there are no
9 additional questions, or follow-up to that, we
10 can conclude the meeting. But if you feel
11 that there are -

12 QUESTIONER 2: One more question.

13 MS. MYRICK-HANCOCK: We have a
14 little bit of information here on the back.
15 The third part of this question is, "Will it
16 be possible for BARDA to provide an electronic
17 copy of today's Q&A presented at today's
18 conference?"

19 The hard copies that have been
20 provided to you as a handout are for your use
21 to take with you when you leave today. We
22 will be uploading the electronic information

1 from the results, the proceedings of this pre-
2 solicitation pre-proposal conference no later
3 than September 19th. So you'll be able to go
4 out and review the information, and download
5 copies. And we actually are having a written
6 record of these proceedings done verbatim so
7 that you'll have the responses to the
8 additional follow-up questions, as well.

9 MR. ANGELASTRO: Okay. Thanks,
10 Paquetta. So if there are -- I'm going to go
11 around the room, and if there are additional
12 questions, nod your head, and we'll wait a few
13 minutes for you to write them down. Otherwise,
14 we can conclude the pre-proposal conference.

15 All right. I'll, again, thank
16 everyone for their attendance. Mike Perdue
17 has a few closing remarks.

18 DR. PERDUE: I do. I was just
19 thinking about how many agencies and sub-
20 agencies have had some direct input into the
21 development of this RFP, and I stopped
22 counting at ten. As you might imagine, the

1 CDC, NIH, FDA, DOD, DHS, a variety of people
2 have had direct input in developing this,
3 because it's a high difficulty, and I just
4 wanted to thank Mike, and Tom, and Paquetta,
5 in particular, for fielding all of this input,
6 and putting together a package that I think
7 ultimately now makes sense to everybody. I
8 think there was great joy at the questions
9 that we got, and the indications from the
10 potential offerors that this was a good idea,
11 and that it was going to work, and so this has
12 been very productive for us.

13 Again, thank you all for coming,
14 and thank you guys for doing a good job.
15 That's all I have.

16 MR. ANGELASTRO: Okay. Thank you.
17 Have a nice weekend.

18 (Whereupon, the proceedings went
19 off the record at 9:57:41 a.m.)
20
21
22

<p>A</p> <p>ability 18:1</p> <p>able 18:5 23:10 30:3</p> <p>accept 8:14 11:4</p> <p>acceptable 14:13</p> <p>accurate 21:6</p> <p>accurately 28:10</p> <p>achieve 12:21</p> <p>acquisition 3:20</p> <p>Acting 3:6</p> <p>activities 18:18,19</p> <p>activity 25:9</p> <p>actual 14:16,20,21 15:1,7 22:1 24:3</p> <p>add 24:6</p> <p>additional 2:17 6:17 6:21 15:17 29:9 30:8,11</p> <p>address 9:8</p> <p>administered 8:16</p> <p>administration 26:11</p> <p>advance 28:10</p> <p>advanced 3:19 17:8</p> <p>advancements 17:7</p> <p>advise 25:19</p> <p>affect 15:22 20:5</p> <p>affiliated 10:4</p> <p>afforded 9:20</p> <p>agencies 30:19,20</p> <p>aggressive 10:18,21</p> <p>agree 27:21</p> <p>agreement 10:1</p> <p>allocable 15:11</p> <p>allow 6:16 10:13 17:2 24:15 29:1</p> <p>allowable 15:11 29:2</p> <p>allowing 16:12</p> <p>allows 10:2</p> <p>Alternatively 16:11</p> <p>amended 9:11 23:15,22</p> <p>amending 10:11 16:9 23:18</p> <p>AMERICA 1:1</p> <p>amount 15:9,10,13</p>	<p>27:22</p> <p>and/or 21:19</p> <p>Angelastro 1:16 2:10 4:13,18 5:19 7:1,8 19:14 20:7 22:22 24:10 29:6 30:9 31:16</p> <p>anonymous 22:18</p> <p>answer 4:3,11 10:15 12:18 13:7,16 15:3</p> <p>answers 19:18 21:22</p> <p>anticipate 10:11 11:19</p> <p>anticipated 15:18</p> <p>application 26:19</p> <p>appreciate 23:6</p> <p>approval 15:6</p> <p>area 9:9</p> <p>arises 26:10</p> <p>asking 23:7 28:5</p> <p>associated 7:19</p> <p>assume 8:18</p> <p>Assuming 12:10</p> <p>assure 4:4</p> <p>Attachment 20:16</p> <p>attendance 6:5 30:16</p> <p>ATTENDEES 2:17</p> <p>attending 23:4</p> <p>Ave 1:14</p> <p>average 8:14</p> <p>avoid 8:7</p> <p>award 10:20 11:2 11:12,14 15:6</p> <p>awarded 7:20</p> <p>aware 3:22</p> <p>a.m 1:13 3:2 22:20 22:21 31:19</p> <p>B</p> <p>back 14:1 19:4 22:10,20 28:11 29:14</p> <p>backdated 11:2</p> <p>BARDA 3:12,22 8:17 12:3 15:16 19:18 29:16</p>	<p>BARDA's 4:1</p> <p>base 19:22</p> <p>based 5:12 8:14,19 10:4 13:14,16</p> <p>basis 8:11</p> <p>behalf 3:12</p> <p>best 9:8</p> <p>better 10:14</p> <p>beyond 25:6</p> <p>billed 15:8</p> <p>billing 8:7</p> <p>biologics 18:4</p> <p>bit 29:14</p> <p>Bob 5:10</p> <p>break 2:14 6:15,19 21:22 22:7,11,13</p> <p>bridging 12:14,19</p> <p>brief 5:21</p> <p>briefly 24:13</p> <p>budget 27:20</p> <p>Building 1:6,13</p> <p>burden 16:10</p> <p>business 8:3,6</p> <p>C</p> <p>calculations 8:19</p> <p>candidate 13:5,11 14:11 17:14 18:13 21:14,18</p> <p>candidates 14:4</p> <p>capacity 8:19</p> <p>captured 12:8</p> <p>cards 6:19 22:4,17</p> <p>CBER 12:20</p> <p>CDC 31:1</p> <p>cell 3:15 5:11 8:21 14:12</p> <p>cell-based 1:6 13:4 13:10,21 14:3</p> <p>challenging 23:9</p> <p>change 26:14</p> <p>changed 3:8 28:14</p> <p>changes 16:15 28:12</p> <p>CHARLES 1:17</p> <p>Charlie 5:3 24:12</p> <p>Christina 1:18 5:17</p> <p>Christmas 11:15</p>	<p>circumstances 16:14</p> <p>clarified 20:8</p> <p>clarify 9:1,15 21:13 23:11</p> <p>classifiable 25:12</p> <p>classified 26:1</p> <p>clause 15:16</p> <p>clinical 12:13,14,16 12:19 13:4,9,15,17 13:22 14:2,12</p> <p>closing 2:20 30:17</p> <p>cognizant 24:22</p> <p>collect 6:19</p> <p>come 28:11,16</p> <p>coming 23:6 31:13</p> <p>commensurate 17:15,21</p> <p>comment 10:7 20:5 24:14,20</p> <p>comments 9:6</p> <p>commercial 25:3 26:9</p> <p>commitment 16:22</p> <p>compared 26:16</p> <p>competitive 11:8</p> <p>compile 10:13</p> <p>complete 21:6</p> <p>completed 20:21 27:16</p> <p>completion 13:3,9</p> <p>compromise 18:1</p> <p>concern 14:8</p> <p>concerning 20:20</p> <p>concerns 9:9 16:20 23:11</p> <p>conclude 29:10 30:14</p> <p>conditions 16:16</p> <p>conducting 12:16</p> <p>conference 1:4,12 3:5 29:18 30:2,14</p> <p>confusion 8:8</p> <p>conjunction 10:3 18:17</p> <p>consider 16:9,11</p> <p>consideration 9:7 10:8 24:22</p>	<p>construction 17:18</p> <p>contact 21:6</p> <p>contingencies 26:22 28:21 29:1</p> <p>contract 4:7 5:16 8:7 11:2,14 15:5 15:19 16:3,21 17:4 17:5,7,16,22 18:19 19:13 20:1 21:11 24:3,4 25:14 26:11 28:2,4,7,13 29:2,5</p> <p>contracting 4:5,18 5:9,14 11:11 15:4 15:7,14 16:4 25:1 25:6,9 27:5</p> <p>contractor 9:8 15:12,21 17:4,22 18:5 25:2 27:8</p> <p>contractors 14:15 16:2,11,12 17:17 18:15</p> <p>contracts 7:20 8:2,9 8:16,17 10:5 16:7 20:6,9,10,12,21 21:1</p> <p>control 19:8</p> <p>convened 1:13</p> <p>copies 29:19 30:5</p> <p>copy 7:7 29:17</p> <p>Correct 20:7</p> <p>cost 14:18,19 15:4 15:16,18,20 16:1,2 16:7 25:13 28:7 29:2</p> <p>costs 7:18,21,22 8:4 14:16,17,20,20,21 15:1,8 25:14 26:14 26:16,19,20,21 27:13,20 28:3,6,10 28:15,20</p> <p>Counsel 5:5 9:12</p> <p>countermeasures 3:21</p> <p>counting 30:22</p> <p>couple 23:8</p> <p>course 8:5 19:9,22 25:11</p> <p>CPFF 26:18 28:4</p>
---	--	---	--	--

29:5 created 7:4 criteria 9:19 13:19 14:5,14 culture 3:15 Curran 1:17 5:3,4 19:6 22:12 24:13 current 15:9 28:14 currently 8:1 12:11 21:1 <hr/> D <hr/> D 2:1 data 8:20 13:15,17 13:22 14:2,12 date 10:12,13,17 11:3 DC 1:14 deadline 6:10 23:16 dealt 26:10 December 11:1,12 11:13 deck 7:12 declared 12:5,5 definition 21:14 definitive 9:9 deliverables 7:19 delivering 3:19 DEPARTMENT 1:2 described 29:3 design 8:18 17:18 detail 7:13 23:7 deteriorate 16:15 determination 15:19 27:9,16 determine 11:8 15:17 19:10 determined 24:22 developing 31:2 development 3:15 3:20 17:8 30:21 device 3:9 DHHS 10:15 24:13 DHS 31:1 difficulty 31:3 direct 30:20 31:2 direction 28:13	Director 3:6 discuss 22:8,13 discussed 24:2 discussion 21:22 diseases 3:10,18 distributing 7:9 division 3:12 4:4,9 5:5 DOD 31:1 doing 31:14 domestic 17:19 doses 12:2,7 double 8:7 download 30:4 Dr 2:6,22 3:5,10,11 4:14 5:10 10:19 23:5 30:18 draft 19:16,19 due 10:16,17 11:10 16:15 duration 16:21 17:3 <hr/> E <hr/> E 2:1 earlier 7:20 23:5 effect 20:13 egg 13:14,16 eight 12:22 13:1 Eldridge 1:17 5:13 5:13 electronic 29:16,22 element 8:6 14:4 21:10 elements 8:1 12:8 eleven 17:12 eligible 17:17 emerging 3:9,17 enable 11:20 endeavor 4:6 equipment 18:16,22 19:11,20 20:12 24:15 25:12,15,18 estimate 8:5 15:21 27:7,12 28:6 estimated 14:19,20 26:16 28:3 estimates 15:2 evaluation 21:9	event 10:5 everybody 3:4 4:17 11:15 31:7 examining 25:20 example 13:14 exceed 15:1 16:2 25:7 exceeded 15:6 exchange 24:21 excuse 24:19 existing 8:9 exit 22:4 expectation 19:19 expedite 21:8 experience 28:15 explosive 3:8 extending 10:17 extent 11:18 25:17 <hr/> F <hr/> face 22:4 facilities 1:7 5:2 facility 8:18 17:1,12 17:19 18:3,3,9,10 18:13,18 fairly 4:6 faith 16:13 far 15:12 19:2,3,6,8 19:10 20:3 24:14 25:22 28:6,22 29:8 FDA 12:17 31:1 FedBizOpps 7:5 fee 14:17,19,21 15:5 15:22 16:3,7 28:8 feel 23:18 29:10 fielding 31:5 fill 11:20 final 8:5 11:9 fine 22:14 24:9 finish 11:20 finishing 12:2 first 4:14 6:3 23:3 23:13 24:11,20 five 10:10 fixed 14:17,19,21 15:5,22 16:3,7 28:8 flexibility 29:4	flu 3:21 follow 21:11 follow-up 6:17 17:10 29:9 30:8 foresee 25:17 formal 7:10 9:18 10:8 formerly 4:19 forward 4:7 21:4 four 9:13 fourteen 21:13 FRIDAY 1:9 front 22:1 full 7:13,16 fully 17:13 fund 15:18,20 27:11 27:17 funded 8:1 12:15,19 12:21 funding 12:11 27:6 funds 15:17 25:16 25:19 furnish 21:6 furnished 25:13 further 20:16 24:14 future 26:20,22 28:6,22 <hr/> G <hr/> G 2:1 General 5:5,5 9:12 genetics 9:22 give 5:6,21 6:14 gives 28:16 go 4:14 6:11 7:12 19:4 23:14 30:3,10 goes 8:5 14:1 25:4 going 5:20,22 6:8,11 6:14,15,16 20:2 23:1,6,14,20 25:7 25:11 27:11,22 28:15 30:10 31:11 good 5:7,19 16:12 23:8 31:10,14 government 4:1,15 8:2,9,14 9:6 16:9 18:7 20:11 24:17 25:2,12,16,18	27:10 government's 9:16 19:19 government-furn... 19:7,12 26:2,6 great 3:14 31:8 group 3:18 guidance 5:6 19:7 guys 4:11 31:14 <hr/> H <hr/> Hancock 5:8 hand 9:21 handout 7:7,9 16:18 29:20 happen 26:7 hard 29:19 Hartman 1:18 5:17 5:17 head 25:8 30:12 Health 1:2 8:22 9:3 9:14,20 10:3,22 11:18 12:12,15 hey 28:12 HHS 1:15 5:18 10:1 10:10 11:13 13:1 16:11 high 4:6 10:21 31:3 highlighted 10:19 highly 26:13 hope 23:10 hopefully 11:13 house 4:15 8:13 Hubert 1:13 Huebner 1:18 5:10 5:10 Human 1:2 9:1,3,15 9:20 10:4,22 11:18 12:12,15 Humphrey 1:13 <hr/> I <hr/> idea 31:10 identified 8:3 15:20 IEDD 3:8 II 19:1 imagine 30:22 include 12:16
---	---	---	--	---

included 7:20 8:4 20:15 26:21 28:20 includes 27:6 including 19:3 incorporate 24:1,4 26:22 28:21 29:1 increase 27:13 28:3 28:15 indemnification 9:2 24:1 Independence 1:13 index 6:18 indicate 22:17 indicated 27:3 indicates 26:18 indications 31:9 influenza 1:6 3:7,9 8:15,20 13:5,10,15 13:17,21 14:3 16:14 17:3,6,9,14 17:20 18:2,6,12 21:20 information 20:20 20:22 21:7 29:14 29:22 30:4 infrastructure 19:21 initial 11:4 input 30:20 31:2,5 instruction 20:17 instructions 21:12 instructs 20:19 insure 21:5 intellectual 9:17,21 intend 26:8 intention 19:14 interacting 4:7 interest 3:14 interfere 18:19 interpreted 14:7 inter-pandemic 14:2,11 introduce 3:5 introduction 2:4 4:16 issue 9:16,17,21 26:3,5,7,9,11 issued 12:3 23:15	I.5 19:1 <hr/> J <hr/> job 31:14 joy 31:8 <hr/> K <hr/> keep 23:20 key 21:10 know 3:14 4:10 6:22 23:5,21 28:9 known 4:20 knows 4:17 <hr/> L <hr/> language 14:22 19:9 20:3 24:5 Law 5:5 Leadership 11:13 leave 29:21 legal 5:6 9:5,14 length 16:21 lengthy 16:19 lessen 16:10 let's 7:17 license 18:6 licensed 9:5 17:13 18:2 licensure 12:13,17 12:21 17:18 18:12 limitation 14:17 15:15 limited 14:18 19:3 26:18 line 10:20 lines 9:14 little 13:1 24:14 29:14 long 13:1 15:10 18:18 look 4:7 22:6 28:12 looking 10:8 14:9 27:11 <hr/> M <hr/> maintain 17:1 18:5 18:11 mammalian 13:4,10	13:21 14:3 Manager 5:1,11 mandatory 13:2,8 13:18 14:5,13 manner 17:1 manufacture 17:13 17:19 18:1,4,6,14 manufactured 8:16 manufacturer 12:6 manufacturing 1:7 8:12 10:5 26:14 market 16:15,16,20 28:14 materials 11:19,21 12:2 mechanism 12:16 meeting 6:1 29:10 meets 10:14 mention 6:3 23:21 mentioned 23:5 merry 11:15 Michael 1:16,21 3:5 Mike 2:6,10,22 4:12 4:18 6:11 30:16 31:4 million 12:6 minute 21:21 minutes 6:15 30:13 missing 27:18 modification 28:1 28:17 modifications 17:5 modify 13:2 morning 5:7 multi-product 18:9 18:10 Murthy 1:19 5:15 5:15 MYRICK-HANC... 1:19 5:7 6:2 7:6 22:3,9,16 24:8 26:12 29:13 <hr/> N <hr/> N 2:1 name 4:17 5:3,8 names 22:17 necessarily 26:3	necessary 24:5 need 22:12 25:5,8 26:22 28:21 needs 6:22 negotiable 26:20 negotiate 16:12 27:19 negotiation 27:14 negotiations 24:3 27:15 new 16:13 nice 31:17 NIH 31:1 nine 14:15 nod 30:12 non-contract 18:17 non-offeror 11:21 non-viable 16:16 note 6:17 17:7 20:4 notes 11:16 notice 16:18 noticed 7:2 notification 16:3 27:4,6 notified 15:14 November 11:9 number 7:18 8:10 8:22 9:7,13 10:7 10:10 11:17 20:17 <hr/> O <hr/> object 18:7 obligated 15:5,9,10 15:13,18 obligation 20:10 occur 11:22 October 11:7 offeror 12:11 17:1 20:20 21:2 offerors 8:18 10:13 11:11 31:10 offeror's 8:21 21:19 Office 4:5 5:4 15:4 Officer 4:20 5:9,14 11:11 15:7,14 16:4 25:1,6 27:5 Officer's 4:19 Okay 3:3 4:13 6:2	11:17 24:10 29:6 30:9 31:16 once 15:12 22:10 27:5,12,15,21 opportunity 4:2 17:5 27:19 28:11 28:16 option 16:13 options 9:8 order 17:20 outline 11:6 outlines 10:18 overall 5:1 7:21 overrun 15:19,20 16:1 overview 5:21 ownership 19:20 20:1,11 <hr/> P <hr/> package 31:6 pandemic 1:6 3:7 3:17,21 8:11 9:2 10:6 12:5,6,13,18 13:14,17 14:9 17:2 21:20 Paquetta 1:19 5:8 5:20 7:8 23:17 24:6 29:7 30:10 31:4 part 7:19 8:16 9:11 19:1,2 21:3 27:10 27:17 28:19 29:15 particular 31:5 parties 10:2 people 4:4 31:1 percent 15:13 25:5 25:7 27:5 Perdue 1:21 2:6,22 3:6,10,11 4:14 10:19 23:5 30:16 30:18 performance 8:15 18:20 20:15 21:5,8 period 11:10 16:14 20:1 permission 25:6,8 permitted 19:9
--	--	---	--	--

<p>perspective 25:22 Phase 13:3,9 place 10:2 20:6 players 4:17 please 4:9 6:7,22 17:7 20:4,16 21:5 21:11,13 22:16 plus 14:16,19,21 15:4 16:2,7 26:15 28:8 portion 28:4 position 9:1,16 28:18 possible 11:3 23:14 29:16 posting 7:4 potential 3:17 16:10 28:2 31:10 potentially 9:19 pre 21:19 30:1 preamble 7:15 14:8 16:19 predict 28:9 prepared 6:9 prerequisite 13:5 13:11 PRESENT 1:15 presentation 6:12 6:17 presented 29:17 pretty 16:6 prevail 16:17 previous 20:5,8 pre-pandemic 21:16 pre-proposal 1:4,12 30:2,14 pre-submitted 7:11 27:2 prior 23:16 priority 10:21 proceedings 3:13 5:22 7:3 22:19 30:1,6 31:18 process 11:6 21:1 29:3 produced 3:15 product 24:18</p>	<p>production 8:12 17:2 24:17 productive 31:12 products 18:14 profile 4:6 program 3:7,18 4:8 5:1,2,11 Project 4:20 projected 8:11 property 9:17,21 19:8,12 25:3,13 26:2,6 proposal 7:21 8:3,6 10:12,14,15,17 13:6,12 19:16 21:3 21:8 23:7,16 26:21 28:20 proposals 11:5,9 propose 17:5 proprietary 24:16 provide 6:20 19:6 20:16 22:10 27:20 29:4,16 provided 9:10 19:18 29:20 provides 24:21 28:11 provision 24:19,20 provisions 19:1,2 purchased 18:16,22 purchasing 25:15 purpose 17:16 purposes 19:12 24:16 25:18 26:9 put 22:17 putting 31:6 P-R-O-C-E-E-D... 3:1 p.m 10:16</p> <hr/> <p>Q</p> <p>question 7:14,18 8:10,13,22 9:5,10 9:13,14 10:6,10 11:17 12:10,22 13:1,7,13,20 14:1 14:7,15 16:8 17:12 18:15 20:14 21:13</p>	<p>22:13 23:13 24:11 24:11 25:10 26:13 27:2,18 28:19 29:12,15 QUESTIONER 22:8,15 29:12 questionnaire 20:15 21:3,4 questionnaires 20:17 questions 2:9,17 4:3 4:11 6:9,18 7:10 7:14 14:7 19:17 20:8 22:6 23:1,8 23:11 29:9 30:8,12 31:8 quick 4:16 Q&A 11:10 16:18 22:2 23:22 29:17</p> <hr/> <p>R</p> <p>range 11:8 rapid 3:16 reach 27:5 reaches 15:13 readiness 17:15,21 reading 14:6 realized 11:3 really 14:10 23:8 reasonable 15:11 reasons 28:8 received 19:17 recognize 28:5 recommendations 11:12 reconvene 22:2 record 22:20,21 30:6 31:19 recording 7:3 recovery 14:18 reference 21:16 referenced 10:11 references 21:5,7 refers 21:19 regarding 23:12 regardless 15:1 reimbursed 14:16 15:9</p>	<p>related 18:17 remain 17:14,20 22:18 remains 15:22 20:13 remarks 2:20 30:17 remember 19:15 25:13 remove 13:2 removed 13:12 Representative 4:19 request 28:17 requested 9:3 require 21:2 required 12:12,17 12:20 requirement 5:9 13:3,8 23:12 requirements 10:14 respond 23:10 responded 27:3 response 3:16 7:21 9:10 10:6,9 26:17 27:18 responses 2:9 6:9 6:13,21 7:10 22:1 22:10 24:1 30:7 responsible 3:19 restricted 9:19 result 27:21 28:1 results 30:1 reverse 9:22 review 6:20 22:6 30:4 revised 15:21 27:7 27:12,20 revolving 9:22 re-assorted 9:22 RFP 7:11 8:1 9:4,11 10:12 12:3,4 14:22 16:9,22 17:17 18:16,22 19:2,5,10 20:3 21:15 23:15 23:18,22 25:21 26:17,17 30:21 RFP-HHS-BARD... 1:5</p>	<p>right 7:5,9 22:22 26:12 30:15 rights 18:21 20:2 risk 16:5 ROBERT 1:18 role 3:22 4:1 room 1:13 7:2 30:11 round 11:4 rules 25:20</p> <hr/> <p>S</p> <p>satisfy 13:18 14:4 14:13 says 28:20 schedule 10:19 Schuyler 1:17 5:13 se 19:21 seasonal 8:20 13:14 13:16,20 14:3,11 17:19 18:2,6,12 21:16,19 second 13:13 24:11 28:19 Secretary 3:14 10:22 Section 19:1 see 6:20 7:13 17:10 Senior 5:11 sense 31:7 separate 12:7 September 1:10 10:11,16 11:5,7 23:17 30:3 serve 5:1 Services 1:2 9:1,4 9:15,20 10:22 11:18 12:12,15 Service's 10:4 set 25:20 setup 16:6 seven 12:10 share 20:11 sharing 25:14 shooting 11:1 shortage 11:21 side 4:15 5:6 8:13 signed 6:5,6 signing 24:4</p>
--	--	--	---	--

similar 9:14 10:6 situation 16:1 situations 8:8 six 11:17 slide 6:12 7:12 10:18 soil 3:16 solely 27:9 solicitation 4:21 12:7,9 18:11 19:15 19:21 20:19 30:2 sort 3:19 5:6 12:1 Specialist 5:16 specifically 13:8 24:17 specified 21:7 spelled 20:2 standard 16:6 start 3:4 started 7:17 23:1,3 starting 11:6 state 17:15,21 stated 16:22 STATES 1:1 status 9:15 stockpile 5:12 stockpiled 11:19 stopped 30:21 strain 8:12 strains 8:15,20 14:10 structure 5:22 studies 12:14,19,20 sub 30:19 subject 12:3 14:17 19:1 27:14 submission 10:12 10:16 13:6,12 19:16 23:16 submit 20:18,20 21:2 submitted 6:10 13:15,18,22 15:21 26:17,19 27:7,12 substantially 26:15 substrate 8:21 14:12 successful 13:3,9	suggested 14:22 support 7:22 17:6,8 17:17 27:13 28:17 supporting 18:10 sure 4:16 6:4 7:16 SW 1:14 syringes 12:1 system 23:19 <hr/> T <hr/> table 22:5 take 6:11 21:21 22:6 24:12 29:21 taken 9:6 talking 11:22 talks 3:9 target 11:1 technical 4:19 7:22 28:13 technology 10:1,3 16:15 17:6 tell 12:4 ten 16:8 30:22 term 21:14,15,18 terminate 16:13 terms 16:13 17:15 17:21 18:8 text 7:16 thank 4:13 5:19 23:4 29:6 30:15 31:4,13,14,16 Thanks 3:11 30:9 things 6:3 12:1 think 3:21 25:21 26:1,3 27:2 31:6,8 thinking 30:19 third 13:20 26:13 29:15 thirteen 20:14 THOMAS 1:22 three 8:22 10:7 20:21,22,22 threshold 25:10 26:5 threshold-basis 19:11 time 10:20 15:16 23:19 25:2 26:8	Title 18:21 today 4:2 7:3 23:4 29:21 today's 3:13 5:21 29:17,17 Tom 4:22 31:4 top 4:3 total 15:4 16:2 25:5 28:3 transcript 7:4 trial 14:2 trials 12:13,17 13:4 13:10 turn 4:10,11 5:20 22:4 two 6:3 8:10 <hr/> U <hr/> ultimately 31:7 unchanged 16:1 Unfortunately 28:22 UNITED 1:1 unknowns 27:1 28:22 uploading 29:22 use 10:2 18:21 19:7 24:15 25:2,3,5,5,7 25:15,17 26:8,8 29:20 uses 19:8 utilize 18:16 utilized 18:4 U.S 4:1 8:2,13 9:15 18:7 24:17 <hr/> V <hr/> vaccine 1:7 8:11 9:2 9:5 11:20 12:14,18 13:5,11,15,17,21 14:4 17:3,6,9,14 18:2 21:14,16,17 21:18,20 vaccines 3:16 5:12 17:20 variety 31:1 verbatim 30:6 vials 11:22	Vijaya 1:19 5:15 <hr/> W <hr/> wait 30:12 waiver 9:18 want 8:7 23:4 24:6 wanted 7:13,16 31:4 Warf 1:22 3:3 4:22 4:22 20:4 warm 10:4 Washington 1:14 way 16:10 29:4 weekend 31:17 weighing 9:7 welcome 3:4,13 went 22:19,20 31:18 we'll 6:19 7:12 11:8 11:14 21:21 22:2,5 22:9 30:12 we're 5:22 6:8,14,15 6:16 7:3 9:11 10:8 10:17 11:1,22 22:22 23:10,13,19 27:11,11 28:14 willing 13:2 wired 7:2 work 11:3 31:11 working 5:11 9:11 write 30:13 writing 15:7,15 16:4 written 30:5 <hr/> Y <hr/> years 20:22 26:15 yield 8:14,19 yields 8:12 <hr/> 1 <hr/> 10-15 21:21 12 1:10 18:15 13 20:16 15th 11:1,14 15-20 6:15 150 12:6 19th 30:3	2 <hr/> 2 22:8,15 29:12 20 26:15 200 1:13 2008 1:10 22 2:14 23 2:17 25 25:4,7 28th 11:7,9 29th 10:12,16 11:5 11:7 23:17 <hr/> 3 <hr/> 3 2:4 10:16 30 2:20 325A 1:13 <hr/> 4 <hr/> 45 19:3 45.301 24:14 45.301(f) 19:4 24:20 24:21 <hr/> 5 <hr/> 5th 11:12 <hr/> 7 <hr/> 7 2:9 75 15:13 27:5 <hr/> 9 <hr/> 9:00 1:13 9:06 3:2 9:27:02 22:20 9:47:19 22:21 9:57:41 31:19
--	---	--	---	--